Small breast epithelial mucin as a useful prognostic marker for breast cancer patients

Hui Hao; Lin Yang; Bingsheng Wang; Yinzhou Sang; Xueliang Liu

doi:10.1515/biol-2022-0784

Small breast epithelial mucin as a useful prognostic marker for breast cancer patients

Open Life Sci. 2023 Nov 23;18(1):20220784. doi: 10.1515/biol-2022-0784. eCollection 2023.

Authors

Hui Hao¹, Lin Yang¹, Bingsheng Wang¹, Yinzhou Sang², Xueliang Liu³

Affiliations

¹ Department of Oncology, Cangzhou People's Hospital, Cangzhou, 061000, China.
² Department of Pathology, Cangzhou People's Hospital, Cangzhou, 061000, China.
³ Breast Center, Cangzhou People's Hospital, Cangzhou, 061000, China.

Abstract

This study aimed to evaluate the clinical utility of small breast epithelial mucin (SBEM) as a prognostic biomarker in an independent patient cohort. The paraffin-embedded tissues and clinicopathological data of 105 patients with breast cancer were collected, and the expression of SBEM in breast cancer samples was detected by immunohistochemical staining. The correlations between clinicopathological variables and the expression of SBEM were analyzed, and its significance as a prognostic indicator for breast cancer patients was determined. Immunohistochemical staining revealed that SBEM was expressed mostly in the cytomembrane and cytoplasm, with markedly increased SBEM expression (≥4 points on staining intensity) observed in 34 of 105 breast cancer tissues (32.4%). Elevated expression of SBEM was found to be significantly associated with larger tumor size (P = 0.002), more frequent lymph node metastasis (P = 0.029), advanced tumor node metastasis stage (P = 0.005), reduced expression of the progesterone receptor (PR) (P = 0.002), and a higher Ki-67 index (P = 0.006). Survival analysis indicated that patients with elevated SBEM expression had worse overall survival (OS) (5-year OS rate: 50.5 vs 93.9% for high and low SBEM expression, respectively, P < 0.001) and disease-free survival (DFS) (5-year DFS rate: 52.8 vs 81.7% for high and low SBEM expression, respectively, P = 0.001) rates than those with low expression of SBEM. Univariate and multivariate Cox analyses demonstrated that elevated expression of SBEM (hazard ratio [HR] = 1.994, 95% confidence interval [CI]: 1.008-3.945, P = 0.047), tumor size (HR = 2.318, 95% CI: 1.071-5.017, P = 0.033), and PR status (HR = 0.195, 95% CI: 0.055-0.694, P = 0.012) were independent predictors of OS in breast cancer patients. Elevated expression of SBEM was associated with both aggressive tumor characteristics and poor survival, indicating its potential as a useful prognostic biomarker for breast cancer patients.

Keywords: biomarker; breast cancer; immunohistochemistry; prognostic; small breast epithelial mucin.